Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autoimmunity in AMD and Response to Ranibizumab
NCT00931489Phase 2Completed
- Sponsor
- Lawrence S. Morse
- Start
- Aug 2009
- Primary completion
- Jun 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Lawrence S. Morse. Started Aug 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00931489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00931489.